HomeNewsBenefits & Pensions About UsContact Us

 Magazine Archives
 News Archives
 Calendar
 Money Managers
 Group Insurers
 Consultants
 Custodians
 Associations
 Careers
 Links
 Canadian Investment Review
 Canadian Healthcare Manager

Current issue is available online







The most current pension and investment information available in Canada, located in these easy to use directories. Click on any logo for information.

© Copyright 2000 Rogers Media. The following article first appeared in the January 2000 edition of BENEFITS CANADA magazine.

New drugs and liability

Is your drug plan a lawsuit waiting to happen? As blockbuster drugs tumble into Canada, make sure that your plan has a plan.

By Hugh O'Reilly

Recently, a number of high-profile drugs, including Viagra, Celebrex and Xenical, have been introduced into the Canadian marketplace. Drugs of this nature create special issues for employers who sponsor prescription drug plans. Many of these drugs are expensive and may result in increasing employee demand.

A decision to exclude certain drugs from a benefits plan could give rise to employer liability if the process is not properly handled.

To make matters even more complicated, it would also seem that we are at the beginning of a cycle in which a large number of what some people call lifestyle drugs will be introduced into the marketplace.

In order to best protect yourself from liability you need to plan ahead, communicate with your plan members and consider implementing novel benefits plan designs.

Whenever a drug is excluded from a drug plan an employer runs the risk that an employee will claim that the exclusion constitutes discrimination under human rights legislation.

While it is not possible to predict how such a claim would be adjudicated by a human rights commission, it is possible to suggest some steps that might lessen the likelihood of such a claim.

First, employers should consider an open and ongoing dialogue with employees. The philosophy and purpose of the drug plan should be properly explained to employees. For example, is the purpose to provide all drugs to all employees or is the plan intended to assist employees in purchasing prescription drugs?

If the purpose is not properly explained, employees may well assume that the plan will provide them with every drug a doctor prescribes. From an employee relations, as well as a human rights, perspective it is important to manage employee expectations.

How can plan sponsors tackle this issue most effectively? Fred Holmes, senior consultant at Buck Consultants Limited in Toronto says addressing the issues from a benefits plan design perspective is a great place to start.

He believes that the type of plan an employer implements should reflect its overall philosophy. Some employers might consider a restricted formulary. This model excludes certain drugs or therapeutic classifications from coverage. In the absence of a proper communications process it may give rise to employee discontent that could translate into legal claims.

Holmes believes that employers should consult with a team of advisers to develop a restricted formulary. Consultation should result in the plan sponsor being in a better position to meet plan member relations and legal challenges.

A more interesting concept, Holmes contends, is a plan that provides life-sustaining drugs and a set sum of money per month on a co-pay basis for employees to purchase prescription drugs. This type of model provides cost containment to employers, covers catastrophic illnesses and is likely to be seen as fair by employees.

A more novel model is a group registered medical savings plan (RMSP). This model would be similar to a registered retirement savings plan and, depending on how it is designed, would require an amendment to the Income Tax Act.

Both the plan sponsor and members would contribute to the RMSP. Contributions could be used to purchase individual health insurance policies or to accumulate funds and disburse funds to pay for required prescriptions.

The advantage of this type of model is that it gives plan members a great deal of control over their drug benefits and allows them to tailor the plan to fit their needs.

We are at the beginning of a new era in which a large number of high-profile--and expensive--drugs will be introduced. Says Holmes: "The challenge presented by these new drugs is made even more interesting because it is occurring at a time when both employers and governments are cost-shifting to employees."

Based on this perspective, it would seem that advance knowledge is power. Whatever plan design you choose, you can't lose by being proactive, planing ahead and communicating with your members. You'll have a better chance of maintaining a positive workplace environment--and protecting yourself from legal liability.

Hugh O'Reilly is a lawyer with Tory Tory in Toronto.


 























Click here to enter:
6th Annual Communication Awards

Sponsored by:

 

 

The Group Internet Directory is now online. Click below to download the PDF.
English | French

The Romanow Commission has released its final report on the future of healthcare in Canada.

For Commissioner Romanow's recommendations, click here.

Click here for Senator Michael Kirby's report, "The Health of Canadians – The Federal Role: Recommendations for Reform."

About Us News Magazine Archives Benefits & Pensions
Links Careers Calender Contact UsHome